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Asthma is a complex disease regulated by the interplay of a large number of underlying mechanisms which contribute to the
overall pathology. Despite various breakthroughs identifying genes related to asthma, our understanding of the importance of the
genetic background remains limited. Although current therapies for asthma are relatively eﬀective, subpopulations of asthmatics
do not respond to these regimens. By unlocking the role of these underlying mechanisms, a source of novel and more eﬀective
treatments may be identiﬁed. In the new age of high-throughput technologies, gene-expression microarrays provide a quick
and eﬀective method of identifying novel genes and pathways, which would be impossible to discover using an individual gene
screening approach. In this review we follow the history of expression microarray technologies and describe their contributions to
advancing our current knowledge and understanding of asthma pathology.
1.Introduction
Asthma is a complex chronic inﬂammatory disease which
aﬀects ∼300 million individuals worldwide, causing an es-
timated economic cost of $19.7 billion in direct and indirect
costs each year [1, 2]. Asthma can be deﬁned by a number
of characteristics, including (1) airway hyperresponsiveness
(AHR), (2) airway remodeling, and (3) airﬂow obstruction
includingbronchoconstriction,mucusplugging,andinﬂam-
mation [3]. The presence and severity of these characteristics
can be inﬂuenced by many factors including age, ethnicity,
gender, genetic predisposition, and the environment [4–
7]. The asthma phenotype is further confounded by the
existence of possible subtypes of asthma, which go beyond
the common mild, moderate, and severe groupings [8].
This heterogeneity has thus far been a major hindrance
in the search for susceptible genes for asthma, and it is
becoming increasingly apparent that asthma is the result
of dysregulation of a number of complex pathways instead
of any single gene. In a new age of high-throughput
technologies, gene-expression microarrays provide a quick
andeﬀectivemethodofidentifyingnovelgenesandpathways
which would be impossible to discover using an individual
gene screening approach. Programs used to analyse and
identify signiﬁcant pathways based on microarray data have
previously been reviewed [9] and will not be discussed here.
In this review we will follow the history of gene-expression
microarray technologies and describe their contributions to
our current understanding of asthma pathology.
2. Methods for Identifying Disease
CausingGenes
Since early evidence for a genetic component for asthma
was most strongly demonstrated by a higher concordance
for asthma among monozygotic than dizygotic twins [10],
the search for genes inﬂuencing this disease has relied
on three main approaches: genomewide association studies
(GWASs)/locus ﬁne mapping, gene candidate approaches,
and gene expression studies (gene-expression microarrays).
The ﬁrst two methods have been extensively reviewed [11,
12] and therefore will only be brieﬂy mentioned here.
GWASs have been essential in the discovery of many asthma-
associated genes including disintegrin and metalloproteinase2 Journal of Allergy
domain-containing protein 33 (ADAM33) (the extensively
studied gene thought to be involved with airway remodel-
ing),inactivedipeptidylpeptidase10(DPP10),neuropeptide
S receptor 1 (NPSR1), histocompatibility antigen, class I,
G (HLA-G), and PHD ﬁnger protein 11 (PHF11) [12–16].
GWASs rely on the variation of genes or surrounding DNA
which occurs between individuals and uses this variation to
measure the probability that certain single nucleotide pol-
ymorphisms (SNPs) (changes to the DNA sequence which
may result in changes to the amino acid sequence of a
protein) are linked to a disease. Because no prior knowledge
of gene function is required, GWASs are considered an
unbiasedtechnique.Incontrast,thegenecandidateapproach
only looks at a speciﬁc region of the genome within or
surrounding a gene of interest.
Gene-expression microarrays provide a platform to mea-
sure and compare the expression level of all genes within a
genome at a single point in time. This platform therefore
allows users to identify genes/microRNAs (miRNAs) which
may be up/downregulated when comparing diﬀerent types
of tissue (e.g., diseased versus normal) or stimulations with
certain drugs (treated versus untreated). Like GWAS, gene-
expression microarrays are considered an unbiased tech-
nique allowing for the identiﬁcation of truly novel genes.
Furthermore gene-expression microarrays provide a tool to
genetically proﬁle diseases, helping to separate diseases into
subtypes or predict the outcome of certain treatments. De-
spite numerous advantages, the use of gene-expression mi-
croarrays in asthma research is still in its infancy.
3. Macroarrays:Where It All Began
Macroarrays were the predecessors to the current day gene-
expression microarray; they had the ability to test anywhere
between 500 and 18000 cDNA transcripts, which were usu-
ally spotted onto a nylon membrane by an arrayer (a device
connected to a computer allowing for precise placing and
cataloguing of samples on an array) (Figure 1)[ 17]. The
cDNAspottedontomacroarrayswasobtainedfrombacterial
libraries, which were developed by inserting total human
transcripts into bacteriophage vectors and transfecting these
vectors into bacteria, usually Escherichia coli. These vec-
tor carrying bacteria were grown and pure colonies were
sequenced and ampliﬁed by PCR prior to being spotted on
am a c r o a r r a y .
Target transcripts for macroarrays were usually radio-
actively labeled by reverse-transcribing sample RNA with
33phosphate-deoxyribonucleotide triphosphates (33P-dNT-
Ps). Samples were then hybridized to the spotted macroarray
and quantiﬁed by measuring the amount of radio-emission
from each spot. Diﬀerential gene expression was calculated
by comparing the emission intensity of samples spotted
on to duplicate macroarrays. Despite being the ground-
breaking technology of their day, macroarrays had a number
of problems. The main limitations of macroarrays were
the low density of probes per array (fewer genes could be
investigated per array), the large volumes of sample required
for hybridization (up to 50mL compared with 200μL used
for current gene-expression microarrays), and the reliability
of the bacterial libraries. In some cases the bacterial libraries
were not composed of pure colonies (not all bacteria in
a single spot contained the same cDNA insert) making it
diﬃcult to determine which transcript was represented by a
particular spot on the macroarray.
4. Gene-ExpressionMicroarrays
Microarrays were the next step forward in the evolution
of gene expression studies, with the advances in array
technology being pioneered by Patrick Brown’s laboratory
[18]. Microarrays, unlike their predecessor, were spotted
onto glass slides allowing for a higher density of probes
(decreasing the amount of sample required to interrogate the
same number of genes) and no longer used radio-actively
labeled nucleotides. These arrays were created using a precise
xyz robot that was programmed to spot cDNA samples on
the substrate in precise locations to allow identiﬁcation of
genes with expression changes during the analysis phase
of the experiment [18]. A number of technologies have
been released using this platform including the dual color
microarray (or two-color microarray) process explained in
Figure 2 and these have been reviewed previously [17]. An
alternative technology for the production of microarrays was
developedusingphotolithographicmaskstocreatetemplates
to enable in situ synthesis of oligonucleotides (usually 20–
30bps) directly on the glass substrate. Aﬀymetrix pioneered
the use of this platform of array production with the
development of their “GeneChip” series of arrays, and in this
review we will focus on the 3  in vitro transcription (IVT)
Expression GeneChip, as the majority of asthma-related
studies have been conducted using this platform; however
there are a large range of other expression microarrays
produced by other companies which have been previously
reviewed [19].
5. 3  IVT ExpressionMicroarrays
The3  IVTarraymicroarrayishistoricallythemostcommon
platform used by researchers conducting gene-expression
microarrayexperimentsintheasthmaresearchﬁeld.Theini-
tial asthma gene-expression microarray studies using human
cells were conducted in 2001 on the Aﬀymetrix Hugene FL
microarray containing probes representing ∼6,500 human
genesfromtheUniGeneBuild18,GenBank,andtheInstitute
for Genomic Research (TIGR) databases (Table 1). As gene-
expression microarray technology advanced and mRNA
databases became more complete, further versions of this
platform were released, increasing the number, speciﬁcity,
and annotation of the microarray probes with each sub-
sequent release (Table 1). In 2004, the asthma community
turnedtotheAﬀymetrixGeneChip95A,thesuccessorforthe
Aﬀymetrix Hugene FL microarray, containing probes for ∼
12,000 full-length genes, derived from sequences in UniGene
Build 95A (created from GenBank 113 and dbEST/10-02-
99), including all the sequences represented on the Hugene
FL microarray (Table 1).
In recent years, Aﬀymetrix has released the Aﬀymetrix
GeneChip Human Genome U133 (HG-U133) containingJournal of Allergy 3
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Figure 1: Overview of the production and use of Macroarrays. Macroarrays were constructed from cDNA held within bacterial libraries.
These libraries were developed by inserting total human cDNA into bacteriophage vectors and transfection into bacteria. Pure colonies
of bacteria carrying vectors were sequenced and ampliﬁed by PCR prior to spotting on to a macroarray. Samples were labeled by
reverse-transcribing mRNAwith radioactively labeled 33phosphate-deoxyribonucleotide triphosphates (33P-dNTPs) using speciﬁc oligo(dT)
primers. Labeled cDNA samples were hybridized to duplicate macroarrays where gene expression was quantiﬁed by comparing the radio-
emissions of each spot.
probes representing ∼33,000 genes (created from GenBank,
dbEST, and RefSeq) followed by their most recent version,
the Aﬀymetrix GeneChip Human Genome U133 Plus 2.0
array, which contains all the probes from its previous version
plus those for 6,500 new genes (Table 1).
5.1. Preparing Samples for Analysis on the 3  IVT Expression
GeneChip. Although many versions of the 3  IVT array
have been released, the methods for preparing samples for
these microarrays remain mostly unchanged. To prepare
the samples for the 3  IVT array, mRNA is ﬁrst extracted4 Journal of Allergy
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Figure 2: Overview of the production and use of expression microarrays. 3  Expression arrays use synthetically derived oligo probes with
design based on mRNA Databases (RefSeq mRNAs, GenBank mRNAs, and ESTs from dbEST) or cDNA derived from bacterial libraries (see
Figure 1). Sample mRNA can be labeled using two methods (a) Cy3/Cy5 labeling: sample mRNA is reverse transcribed into cDNA and Cy3
is added to one sample and Cy5 to another. Both labeled samples are hybridized to the same microarray. (b) 3  IVT array: sample mRNA
is reverse transcribed to cDNA using oligo(dT) primers, to provide a template for transcription. Using biotin-conjugated nucleotides, the
template cDNA is then converted to ampliﬁed RNA (aRNA). The biotin-labeled aRNA samples are then fragmented and hybridized onto 3 
expression arrays. A biotin binding ﬂuorescent stain is added to the microarray after hybridization. (c) Aﬀymetrix HuExon 1.0 ST: sample
mRNA is reverse transcribed to cDNA using random primers, to provide a template for transcription. The resulting RNA is then reverse
transcribed in the presence of dUTPs which are incorporated occasionally into the cDNA sequence instead of dTTP. An enzyme is then
used to cleave the cDNA at the site of dUTP incorporation and fragments are terminally labeled before hybridization onto the array. The
microarray is then washed and stained after hybridization.
from the targeted sample and converted to cDNA via
reverse transcription using oligo(dT) primers attached to
aT 7p r o m o t e r( Figure 3). Oligo(dT) primers are short
strings of dTs which selectively bind to the poly-A tails
(of mRNA). Although this process was quite successful in
binding to the majority of mRNAs, transcripts without
poly-A tails (non-polyadenylated) were lost during this
step. Current technology for the purpose of priming for
reverse transcription uses random hexamers (strings of
six random dNTPs) which capture sequences at any loca-
tion along a transcript. This will be discussed later (see
Section 8).
The cDNA is then converted to double stranded DNA
(using the T7 promoter), to provide a template for transcrip-
tion.Usingbiotin-conjugatednucleotides,thetemplateDNA
is then converted to ampliﬁed RNA (aRNA). The biotin-
labeled aRNA samples are then fragmented and hybridized
onto 3  expression arrays and visualized by staining with
phycoerythrin.
5.2. 3  IVT Expression GeneChip Probes. Unlike the ma-
croarrays previously described and a number of other
gene-expression microarrays available on the market, 3  IVT
Expression GeneChips do not use cDNA libraries spotted
onto an array. Instead Aﬀymetrix arrays use short (∼25bp)
nucleotide probes synthesized directly on the array; this
process is well explained in a previous review [17]. Gene
expression is determined by the hybridization of transcripts
to perfect match (PM) and mismatch (MM) probes.
Transcripts will preferentially bind to PM probes as they
provide a perfect complimentary sequence to their matching
transcript. MM probes are designed to resemble PM probes
but diﬀer (change in a single nucleotide) just enough for
the target transcript not to bind. Therefore any transcripts
binding to these MM probes are considered to represent
background hybridization; by the use of the function
(PM hybridization, MM hybridization) background
hybridization can be calculated and taken into account.
However, the use of MM probes to identify background
binding has been slowly phased out because of a variety of
technical reasons including the occurrence of “negative”
expression levels when expression is low and the MM
intensity exceeds the PM. For example, the R-Bioconductor
preprocessing pipelines frequently omit MM probes
[20].Journal of Allergy 5
Table 1: Databases used in Aﬀymetrix microarray annotation.
Database Description Website References
Expressed Sequence Tag
Database (dbEST)
Division of GenBank that contains
“single-pass” cDNA sequences (only
sequenced once), or “Expressed
Sequence Tags”
http://www.ncbi.nlm.nih.gov/dbEST/ [78]
The Institute for Genomic
Research (TIGR)
Constructed by clustering, then
assembling expressed sequence tag
(EST) and annotated gene sequences
from GenBank
http://compbio.dfci.harvard.edu/tgi/ [79]
UniGene Build
Contains transcript sequence
information including: protein
similarities, gene expression, cDNA
clone reagents, and genomic location
http://www.ncbi.nlm.nih.gov/unigene/ [80]
GenBank Annotated collection of all publicly
available DNA sequences
http://www.ncbi.nlm.nih.gov/genbank/ [81]
The Reference Sequence
(RefSeq)
Contains nonredundant, and
well-annotated genomic DNA,
transcripts, and protein sequences
http://www.ncbi.nlm.nih.gov/RefSeq/ [82]
6. 3  ExpressionArrays:Inﬂuence on
Asthma Research
3  Expression arrays have played a key role in asthma
research through the screening for, and identiﬁcation of,
genes which are aﬀected by asthma relevant stimuli and
the direct comparison of asthmatic tissue to nonasthmatic
tissue. Initial studies for asthma using the 3  platform
focused on identifying key cell types which play a role in
asthma; therefore many researchers conducted their studies
on human-isolated cells expanded in culture. One of the
ﬁrst isolated cell gene-expression microarray studies was
conducted by Lee and group in 2001, where commercially
available primary airway smooth muscle (ASM), epithelial
cells, and ﬁbroblasts derived from human lungs were treated
with 100ng/mL of interleukin 13 (IL13), a cytokine known
to be upregulated in asthma, for 6 hours and run on an
Aﬀym e t ri xH u g e n eF Lm i c r o a rr a y[ 21]. This study identiﬁed
that treatment with IL13 caused dysregulation of a number
of asthma-related genes. Diﬀering eﬀects were observed in
diﬀerent cell types of the airway, promoting the idea that
each cell type plays its own role in asthma [21]. Once the
ball started rolling, the asthma gene-expression microarray
ﬁeld quickly expanded from looking at single treatments on
pure isolated cells in culture to the eﬀects of more complex
interactions including genes expressed during viral infection
and direct comparisons of the gene expression in asthmatic
and nonasthmatic tissue [22]. Although there have been
many murine gene-expression microarray studies analyzing
models of asthma, we have focused on the human studies in
this review.
6.1. Airway Smooth Muscle Cells. T h eA S Mp l a y sak e yr o l e
in the normal constriction and relaxation of the bronchial
airway. In asthma the role of the ASM becomes exaggerated
resulting in excessive airway narrowing in response to
nonantigenic stimuli, termed AHR. A number of factors
have been implicated in promoting AHR including airway
remodeling and inﬂammation. The majority of the ASM
gene-expression microarray studies to date have focused on
the latter parameter and most focusing on the eﬀect of
IL13 [21, 23–25] but a small number have been conducted
on remodeling [26]. In the search for an inﬂammatory
mediator for asthma, IL-13 was found to play a critical role
in murine asthma models [27]. During this time microarrays
were just starting to be used in asthma research and many
researchers took advantage of this new screening technology
to help identify genes stimulated by this inﬂammatory
cytokine. As already discussed the ﬁrst of these studies
was conducted by Lee et al., who identiﬁed a number
of genes which were expressed speciﬁcally by ASM after
treatment with 100ng/mL of IL13 for 6 hours [21]. The
next major study was conducted by Jarai et al. in 2004,
who again looked at the eﬀect IL13 had on ASM cells
and two additional treatments, interleukin-1β (IL1β)a n d
transforming growth factor-β (TGFβ) selected to identify
if diﬀerent inﬂammatory conditions cause ASM cells to
distinct phenotype changes. Jarai et al. conducted this study
using the updated Aﬀymetrix GeneChip 95A array and
stimulated ASM cells separately with 10ng/mL of each
treatment for 4 and 24 hours [23]. Although these authors
conducted this study using cells derived from only two
patients, a large range of genes induced by these three
stimuli were identiﬁed [23]. IL1β stimulation conﬁrmed
the induction of a number of cytokines found in the
literature to be previously upregulated; also a number
of novel genes were identiﬁed including growth-related
oncogene α, β,a n dγ, macrophage inﬂammatory protein
3α (MIP-3α), epithelial neutrophil activating peptide 78
(ENA-78), granulocyte-colony stimulating factor (G-CSF),
and interleukin-1 receptor antagonist (ILRA) [23]. The main
eﬀect of IL13 stimulation on ASM was the induction of the
expression of eotaxin, a strong chemoattractant for Th2-like
T lymphocytes basophils and eosinophils which are found6 Journal of Allergy
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Figure 3: Transcripts from a single gene can undergo diﬀerent splicing events. When mRNA is initially transcribed (known as pre-mRNA),
it retains introns (thick black line), large segments of noncoding mRNA which separate exons, the coding regions. Through a process known
as splicing, the introns are then removed and exons are ligated together to produce mature mRNA. Splicing also has the ability to remove
exons or even retain introns resulting in the formation of diﬀerent mature mRNA transcripts for the same gene (referred to as alternative
splicing). Diﬀerent mature mRNA transcripts encode for diﬀerent proteins which may have alternative functions.
in tissues undergoing allergic reactions [28]. A note made
by the authors was that this gene was not previously picked
up by Lee et al. in their gene-expression microarray study
and this disparity was thought to be due to diﬀerences in
the concentration of IL13 and the sources of the ASM cells.
TGFβ altered the expression of a number of structural and
extracellularmatrixproteinsandalsoincreasedexpressionof
IGF-binding protein 2, which had previously been indicated
to mediate the growth response of TGFβ on ASM cells
[23, 29].
High serum immunoglobulin E (IgE) levels have long
been associated with allergic asthma [30]. In 2000 an asso-
ciation study identiﬁed a naturally occurring isoform of IL13
(IL13R130Q) to be associated with elevated serum IgE levels
[27].InanattempttoidentifytheroleofIL13anditsisotypes
in the pathogenesis of allergic asthma, Syed et al. looked at
the eﬀect of IL13 and IL13R130Q on ASM using an expres-
sion microarray containing 8159 human gene cDNA clones
from Research Genetics (IMAGE consortium, Huntsville,
AL), Incyte Genomics (Santa Clara, CA) [24]. No diﬀerences
weredetectedbetweenthegenesinducedbythetwoisoforms
of IL13; however two genes, vascular cell adhesion protein
1 (VCAM1) and IL13 receptor alpha 2 protein chain (IL-
13Rα2), were identiﬁed as being stimulated at both the
mRNA and protein level [24]. VCAM1 had previously been
implicated as a key player in the inﬂammation process;
therefore the microarray further validated the role of IL13
in asthma [24]. IL13 induction of IL-13Rα2 was predicted by
the author and that newly synthesized IL-13Rα2m a ya c ta sa
decoy receptor therefore creating a self-regulating feedback
loop preventing overstimulation of ASM cells, which had
been previously conﬁrmed in murine models [31].
6.2.AirwayEpithelialCells. Theairwayepitheliumliesonthe
outermost layer of the bronchus and hence is positioned to
directlyrespondtoenvironmentalirritantssuchaspollutants
and viruses which are associated with asthmatic exacerba-
tions. Previous studies have shown that asthma epithelium
has alternations in both its structure and gene expression
[32, 33]. The majority of gene-expression microarray studies
focusing on the structural cells of the airway have focused
on the epithelium [34–42]. Following the initial studies
conducted by Lee et al., Yuyama et al. looked at the eﬀect
of Th-2 cytokines on human bronchial epithelial cells (n =
3) by treating them with 10ng/mL of interleukin-4 (IL-
4) and 50ng/mL of IL13 separately for 24 hours before
running the resulting cDNA on a Aﬀymetrix Hugene FL
microarray [34]. This study identiﬁed 2 major genes—
squamous cell carcinoma antigen 1 (SCCA1) and squamous
cellcarcinomaantigen2(SCCA2)whichwerebothincreased
by ∼20foldinbothstimulationscomparedtountreatedcells.
SCCA1 and SCCA2 expression was found to be under the
control of signal transducer and activator of transcription
4 (STAT4), a transcription factor previously found to be
upregulated in epithelial cells derived from severe asthmatics
[34]. Furthermore SCCA1 was found to be upregulatedJournal of Allergy 7
in the serum of asthmatic patients especially during an
asthma exacerbation [34]. Recently both SCCA1 and SCCA2
have been proposed as a method for testing for bronchial
asthma attacks through the use of serum samples or mRNA
expression [43].
In 2003 Kong et al. looked at early gene expression
during a respiratory syncytial virus (RSV) infection of A549
epithelial cells using an Aﬀymetrix Hugene FL microarray
[35]. They found that two pathways, signal transducer and
activator of transcription 1α and 3 (STAT-1α and STAT-3),
were upregulated by RSV-key genes required for successful
infection [44]. Subsequently the microarray identiﬁed 53
geneswhichhadachangeinexpressionduetoRSVinfection,
consistent with changes in gene expression reported in pre-
vious studies [44].
Taking a diﬀerent approach, Chu et al. looked at the ef-
fect of mechanical stress on gene expression in epithelial
cells [36]. During bronchial constriction the epithelial layer
experiences compressive mechanical stress [45], which in
previousstudieshavebeenshowntostimulatetheexpression
of transforming growth factor-β 2 (TGFB2) and endothelin
(ET) facilitating ﬁbrosis of the airway wall, a feature of
asthmatic airways [46]. To identify further genes aﬀected
by mechanical stress, Chu et al. placed epithelial cells un-
der mechanical stress for 8 hours and ran the samples
against a set of pooled controls on Aﬀymetrix Human 133A
DNA microarrays [36]. Chu et al. identiﬁed a number of
plasminogen-relatedgenes(urokinaseplasminogenactivator
(uPA), urokinase plasminogen activator receptor (uPAR),
plasminogen activator inhibitor-1 (PAI-1), and tissue plas-
minogen activator (tPA)) which were upregulated on the
microarray and conﬁrmed both by qPCR and at the protein
level [36]. Activation of the plasminogen pathways was
shown to activate MMP-9, a protein associated with airway
remodeling [47]. These results support the growing body of
evidence that noninﬂammatory stimuli can contribute to the
overall asthma phenotype [36].
In recent years two groups have conducted large screen-
ing for genes diﬀerentially expressed in asthma epithelium
[41, 42]. The ﬁrst of these two studies was conducted in 2007
by Woodruﬀ et al. who compared the gene expression of 42
asthmatics and 44 nonasthmatics (28 healthy subjects and 16
smokers) and also the eﬀect of corticosteroids on asthmatic
patientsusinganAﬀymetrixHuman133A2plusmicroarray.
The authors identiﬁed 22 genes which were found to be
diﬀerentially expressed between asthma and healthy controls
including periostin and serpinB2 and were veriﬁed by qPCR
and at the protein level. The use of corticosteroids in
asthmatic patients was shown to aﬀect 30 genes compared to
a placebo; 5 were veriﬁed by qPCR, including FK506 binding
protein 51 (FKBP51), which had previously been identiﬁed
to modulate glucocorticoid receptor activity [48].
Thesecondstudyconductedin2010byKicicetal.looked
at the expression of children with asthma (n = 36), healthy
atopic (n = 23) and healthy nonatopic controls (n = 53)
using Aﬀymetrix Human 133A DNA microarrays [42]. The
aim of the study was to identify extracellular matrix (ECM)
protein diﬀerentially expressed in asthma. They identiﬁed a
single ECM gene ﬁbronectin (FN) which was signiﬁcantly
lower in asthmatics, veriﬁed by qPCR and ELISA [42].
The authors then silenced FN expression in nonasthmatic
epithelial cells and this was found to inhibit wound repair,
while in the reverse situation the addition of FN to asthmatic
epithelial cells restored wound repair within these cells [42].
Based on these results FN was identiﬁed as an ECM protein
which may contribute to the abnormal epithelial repair seen
in asthmatics.
6.3. Fibroblasts. Currently no further asthma-related gene-
expression microarrays’ studies have been conducted on
human lung ﬁbroblasts following the initial study conducted
by Lee et al. [49]; however a number of arrays have been
conducted on lung ﬁbroblasts from murine models which
have been reviewed elsewhere [50].
6.4. Mast Cells. Mast cells play an important role in asthma
and other allergic disorders. Activation of mast cells by stim-
ulatory factors, such as antigens or IgE, induces the produc-
tion and/or release of cytokines and inﬂammatory mediators
such as histamine. The use of gene-expression microarrays
for human mast cell studies has been limited because of the
diﬃculty of isolating this cell type [51–53]. The initial gene-
expressionmicroarraystudiesconductedonmastcellsaimed
to identify genes which were speciﬁcally expressed by mast
cells. Nakajima et al. compared the expression of periph-
eral blood-derived mast cells, eosinophils, neutrophils, and
mononuclear cells on an Aﬀymetrix GeneChip 95A array
[51]. They identiﬁed 140 genes which were mast cell speciﬁc
and major basic protein (MBP) which were thought to be
eosinophil speciﬁc. Furthermore MBP protein expression
was veriﬁed by ﬂow cytometry and confocal laser scanning
microscopy. MBP is thought to be physiologically important
in asthma as it has previously been found to be deposited in
the damaged epithelium of asthmatic patients [54, 55].
6.5. Tissue. It has long been recognized that smooth muscle
cells expanded in culture lose their contractile function
and receptors with subsequent passaging [56]. The loss of
function has also been noted in other cell types of the
human airways. Therefore, the question has been raised as
to whether gene-expression microarray studies on cultured
cells give a true representation of physiological conditions.
Tissue-based studies therefore provide a glimpse of the genes
expressed under true physiological conditions, but because
thissourceofmRNAisamixtureofcelltypes,itisimpossible
to diﬀerentiate which transcripts are being expressed by
which cell type. One of the few tissue microarray expression
studies, and the ﬁrst 3  microarray study to directly compare
human asthmatic and nonasthmatic tissue, was conducted
by Laprise et al. looking at the expression proﬁle of biopsies
before and after inhaled corticosteroid therapy [22]. Using
an Aﬀymetrix GeneChip 95A, Laprise et al. identiﬁed 74
geneswhichwerediﬀerentiallyexpressedbetweenasthmatics
and nonasthmatics, with a majority of these genes having
already been identiﬁed as asthma related. However a num-
ber of novel genes were also identiﬁed including arachi-
donate 15-lipoxygenase (ALOX15), cathepsin C (CTSC),
and chemokine (C-X3-C motif) receptor 1 (CX3CR1) [22].8 Journal of Allergy
Table 2: Asthma-related phenotypes that result from aberrant expression of splice variants.
Symbol Gene Name Phenotypes Description Reference
NPSR1 neuropeptide S
receptor 1
IgE levels and
Asthma
Isoform B over expressed in asthmatic ASM
cells
[15]
IL-4 interleukin-4 Asthma
Alternatively spliced variants of IL-4 mRNA
are diﬀerently expressed in patients with
bronchial asthma
[58, 59]
COX-1
cytochrome c
oxidase
assembly
homolog (yeast)
Asthma
Alternatively spliced variants of COX-1
mRNA are diﬀerently expressed in patients
with bronchial asthma
[60]
Comparing asthmatic subjects before and after inhaled
corticosteroid therapy identiﬁed 128 genes which had altered
expression in the presence of the therapy. However 70%
of the genes which were upregulated in asthma remained
unchanged after corticosteroid therapy [22]. It was predicted
by the author that a subset of these genes may be responsible
for asthma chronicity [22].
However 3  arrays only provide the user with the overall
level of gene expression without measuring the degree of
contribution of diﬀerent splice variants of the genes being
interrogatedtothetotalgeneexpression.Thisisproblematic,
as a number of key asthma-related genes including NPSR1,
IL-4,cytochromecoxidase assemblyhomolog(yeast)(COX-
11), and ADAM33 have been found to have dysregulation of
alternative splicing patterns and/or diﬀerential expression of
speciﬁc splice variants [15, 57–60].
7.AlternativeSplicing
The human genome contains ∼30,000 genes; however it
has been predicted that there are over 100,000 proteins
expressed in the body. These predictions are in contrast
to the previously well-accepted “one gene-one enzyme”
theory proposed in 1941, where it was believed that each
gene encoded only one protein [61]. Recently, alternative
splicing has been identiﬁed as the process through which this
apparent gene deﬁciency in the human genome is explained.
When mRNA is initially transcribed (known as pre-mRNA),
it retains introns, large segments of noncoding mRNA which
separate exons, the coding regions (Figure 3). Through a
process known as splicing, the introns are then removed
and exons are ligated together to produce mature mRNA
sequences. Splicing also has the ability to remove exons or
even retain introns resulting in the formation of diﬀerent
mature mRNA transcripts for the same gene (referred to as
alternative splicing).
It is now predicted that over 95% of all multiexon
genes in the human genome undergo some degree of
alternative splicing [62]. Depending on what sections of
RNA are removed or retained, alternative splicing can have
major eﬀects on the functionality of the resultant proteins
(Figure 3). Therefore, it is not surprising that a number
of genetic diseases including asthma have been linked with
mutation and changes with cis- (e.g., DNA sequence related)
and trans- (e.g., transcription factors) acting factors which
lead to aberrant splicing and irregular protein production
(Table 2).
The function of disease causing splice variants is still
poorly understood; however, based on previous ﬁndings
(Table 2), studying splice variants may provide an untapped
resource which could hold some answers for their role in
asthma.
8. The Future of Gene-Expression Microarrays:
Affymetrix HuExon1.0 ST
Recent advances in gene-expression microarray design have
producedtheAﬀymetrixHuExon1.0ST;thisplatformallows
for the evaluation of not only gene expression but also
exon level expression and identiﬁcation of unknown splicing
events. The Aﬀymetrix HuExon 1.0 ST contains 65 million
probes, 8 times the number of the probes present in the
latest release of the Aﬀymetrix U133 Plus2 array. The main
diﬀerences between exon arrays and 3  arrays come from
the number and binding sites of the oligonucleotide probes,
labeling methods and diﬀering methods for identifying
background noise levels.
3  arrays simply use 11–20 probes for each gene which
bind to the 3  end, while Exon arrays use ∼40 probes evenly
spaced along all exons of a given transcript. The advantage
of this method is that Exon arrays can detect all isoforms
of a gene transcript and evaluate the level of expression for
each splice variant, while 3  arrays lack this ability as their
probes are only positioned towards the 3  e n do fa nm R N A
transcript.
Another key diﬀerence is the generation of the sample
mRNAduringtheinitialcDNAstep;Exonarraysuserandom
probes (containing 6 random nucleotides) attached to a T7
promoter whereas oligo(dT)s attached to a T7 promoter are
usedastheprimersforthe3  arrays.Byusingrandomprobes
whichbindanywhereonthemRNAtranscript(notrestricted
tothepoly-Atail),Exonarrayshaveovercometheproblemof
identifying non-polyadenylated transcripts by covering the
entire gene transcript, rather than having a 3  bias. Replacing
the function of the MM probe control used by 3  arrays,
Exon arrays use a specially designed set of probes which
should not bind any mRNA to detect background binding.
Exon arrays represent many improvements when compared
to their predecessors and, as the search for disease causing
candidates moves forward, it will only be a matter of timeJournal of Allergy 9
before these arrays receive much greater attention in the
scientiﬁc community.
8.1. Aﬀymetrix HuGene 1.0 ST Microarray. T h eG e n e1 . 0S T
Array was designed based on the Exon 1.0 ST Array (and
therefore uses the same sample preparation and labeling
methods). The key diﬀerence is that it contains only a subset
of the probes, focusing on well-annotated content. Similar to
3  arrays,theAﬀymetrixGene1.0STalsoprovidesaplatform
for measuring genomewide gene expression of a sample at
a single point in time. However, by using probes which are
evenly spaced along all exons, the Aﬀymetrix Gene 1.0 ST
array is able to give a true representation of gene expression
(Figure 2). Gene 1.0 ST arrays also have a limited ability to
identify alternatively spliced gene products; however the low
number of probes per exon means that false positive events
occur more commonly than with the superior Human Exon
1.0 ST Array.
8.2.TheInﬂuenceofExonArrayAsthmaResearch. Atthetime
of writing this review the use of exon arrays in reported
human asthma-related projects was limited to a single study
conducted by Plager et al. 2010 [63]. This study aimed to
identify genes related to asthmatic chronic rhinosinusitis
with nasal polyps (aCRSwNP) and eosinophilic epithelial
inﬂammation, through the use of an Aﬀymetrix HuExon
1.0 ST. Although alternative splicing was not looked at in
this study, Plager et al. identiﬁed a number of chemokines
and chemoattractants including eotaxin-1 (associated with
inﬂammation and upregulated by IL13 [23, 28]), -2, and -3
which were associated with aCRSwNP.
9. MicroRNA
MicroRNAs (miRNA) are short (22 nucleotide) segments
of RNA which bind to complementary sequences on target
mRNA, thereby facilitating mRNA degradation and thus
repressing gene expression at the transcriptional level. miR-
NAs can be transcribed from their own genes or exist within
intronic regions of mRNA. miRNAs are incorporated into
miRNA-argonaute complexes which facilitate their ability to
degrade/inhibit mRNA transcripts (reviewed in [64]). The
human genome is believed to encode over 1000 miRNAs
[65], and these miRNAs are predicted to bind to over 60%
of all mRNA transcripts in the human genome [66]. The
dysregulation of miRNAs has been identiﬁed in a number of
human diseases including asthma [67].
10. MiRNA Microarray:How It Works
There are a large range of miRNA microarrays currently
being oﬀered by a number of companies (Table 3); however,
as yet, the methodology used to analyze these arrays has not
beenstandardized.Inthisreviewwewilldiscussthemethods
used by the mirVana miRNA bioarrays V2 (Ambion) which
were used by Kuhn et al. [67], currently the only miRNA
array conducted on human ASM cells (Figure 4). The
mirVana miRNA bioarray, like a number of other miRNA
microarrays on the market, relies on the addition of a poly
miRNA puriﬁcation
Added
Added
Poly(A) polymerase
dATPs (A) and modiﬁed dATPs (A)
Total RNA
miRNA
AAAAAAAA
Flurescent dye
Sample hybridized to the array
AAAAAAAA
Figure 4: Overview of mirVana miRNA bioarray methodology.
Total RNA is extracted from tissue or cells and miRNA puriﬁed.
Poly(A) polymerase is then added in the presence of modiﬁed
dATPs and normal dATP. A poly(A) tail containing the modiﬁed
dATPs is then added to all RNAs present in the sample. Fluorescent
dye is added which binds to the poly(A) tail and the sample is
hybridized to the array.
(A) tail containing modiﬁed adenosine nucleotides to all re-
maining RNA (after miRNA puriﬁcation) which allows for
the speciﬁc binding of ﬂuorescent dyes, prior to being
hybridized to the array.
miRNA asthma research is still in its infancy, with
the initial report of a human asthma miRNA array study
being made by Kuhn et al. in 2010 [67]. These researchers
looked at the eﬀect of IL-1β,T N F - α,a n dI F N - γ on miRNA
expression in ASM cells using mirVana miRNA bioarrays
V2 (Ambion). miR-25, miR-140∗, miR-188, and miR-320
were found to be signiﬁcantly downregulated, and these
data were veriﬁed by both microarray and quantitative
PCR. Furthermore miR-25 had previously been identiﬁed10 Journal of Allergy
Table 3: List of a number companies currently providing miRNA microarray technology.
Company Microarray Link
Ambion mirVana miRNA bioarrays V2 http://www.ambion.com/
Agilent Technologies Human miRNA Microarray Release 16.0 http://www.genomics.agilent.com/
Aﬀymetrix GeneChip miRNA 2.0 Array http://www.aﬀymetrix.com/
Exiqon miRCURY LNA microRNA Array http://www.exiqon.com/
Invitrogen NCode Human miRNA Microarray V3 http://products.invitrogen.com/
LC Sciences V17.0 Human microRNA Microarray http://www.lcsciences.com/
Miltenyi Biotec miRXplore Microarray Kits http://www.miltenyibiotec.com/
System biosciences miRNome MicroRNA Proﬁlers http://www.systembio.com/
Table 4: The GEO accession number for microarray studies conducted on asthma.
Year Title Array
GEO
accession
number
Reference
Smooth muscle cells
2001 Interleukin-13 induces dramatically diﬀerent transcriptional
programs in three human airway cell types Aﬀymetrix Hugene FL n/a [21]
2004
Eﬀects of interleukin-1 [beta], interleukin-13, and transforming
growth factor-[beta] on gene expression in human airway smooth
muscle using gene microarrays
Aﬀymetrix GeneChip 95A n/a [23]
2005
The eﬀect of IL13 and IL13R130Q, a naturally occurring IL13
polymorphism, on the gene expression of human airway smooth
muscle cells
8159 human gene cDNA clones
from Research Genetics (IMAGE
consortium, Huntsville, AL),
Incyte Genomics
n/a [24]
2007 1α,25-Dihydroxy-vitamin D3 stimulation of bronchial smooth muscle
cells induces autocrine, contractility, and remodeling processes
Human Genome U133 Plus 2.0
GeneChip arrays GSE5145 [26]
2009 Glucocorticoid- and protein kinase A-dependent transcriptome
regulation in airway smooth muscle
Aﬀymetrix Human U133A DNA
microarrays GSE13168 [25]
2010 MicroRNA expression in human airway smooth muscle cells: role of
miR-25 in regulation of airway smooth muscle phenotype
mirVana miRNA bioarrays V2
(Ambion)
GSE16587
GSE16586 [67]
Epithelial cells
2002 Analysis of novel disease-related genes in bronchial asthma Aﬀymetrix Hugene FL n/a [34]
2003 Respiratory syncytial virus infection activates STAT signaling in
human epithelial cells Aﬀymetrix Hugene FL n/a [35]
2006 Induction of the plasminogen activator system by mechanical
stimulation of human bronchial epithelial cells
Aﬀymetrix Human 133A DNA
microarrays n/a [36]
2007 IL-13 and epidermal growth factor receptor have critical but distinct
roles in epithelial cell mucin production
UCSF 9Hs Human 23K v.2 Oligo
Array GSE4804 [37]
2007 Genomewide proﬁling identiﬁes epithelial cell genes associated with
asthma and with treatment response to corticosteroids
Human Genome U133 Plus 2.0
GeneChip arrays GSE4302 [41]
2009
Airway epithelial cells regulate the functional phenotype of locally
diﬀerentiating dendritic cells: implications for the pathogenesis of
infectious and allergic airway disease
Human Genome U133 Plus 2.0
GeneChip arrays GSE12773 [38]
2009 T-helper type 2-driven inﬂammation deﬁnes major subphenotypes of
asthma
Human Genome U133 Plus 2.0
GeneChip arrays GSE4302 [39]
2010 Rhinovirus-induced modulation of gene expression in bronchial
epithelial cells from subjects with asthma
Human Genome Focus
GeneChip Array
Human Genome U133 Plus 2.0
GeneChip arrays
GSE13396 [40]
2010
Transglutaminase 2, a novel regulator of eicosanoid production in
asthma revealed by genomewide expression proﬁling of distinct
asthma phenotypes
Aﬀymetrix Human U133A DNA
microarrays
Human Genome U133 Plus 2.0
GeneChip arrays
GSE13785 [83]
2010 Decreased ﬁbronectin production signiﬁcantly contributes to
dysregulated repair of asthmatic epithelium
Aﬀymetrix Human 133A DNA
microarrays GSE18965 [42]Journal of Allergy 11
Table 4: Continued.
Year Title Array
GEO
accession
number
Reference
Mast Cells
2001
Gene expression screening of human mast cells and eosinophils using
high-density oligonucleotide probe arrays: abundant expression of
major basic protein in mast cells
Aﬀymetrix GeneChip 95A n/a [51]
2005 Amphiregulin expression in human mast cells and its eﬀect on the
primary human lung ﬁbroblasts
Aﬀymetrix Genechip Human
Genome U133 n/a [52]
2009 Human mast cells synthesize and release angiogenin, a member of the
ribonuclease A (RNase A) superfamily
NIAID (human sequence chip
series “sa”) and consist of 13,971
oligonucleotides, synthesized by
Qiagen Operon Inc. (Valencia,
CA, USA)
n/a [53]
Tissue
2004 Functional classes of bronchial mucosa genes that are diﬀerentially
expressed in asthma Aﬀymetrix GeneChip 95A GSE15823 [22]
2010 Gene transcription changes in asthmatic chronic rhinosinusitis with
nasal polyps and comparison to those in atopic dermatitis Aﬀymetrix HuExon 1.0 ST GSE5667 [63]
GEO:NCBI Gene Expression Omnibus.
n/a: microarray data not submitted to a database or not stated in paper.
to regulate Kr¨ uppel-like factor 4 (KLF4), a mediator of
proinﬂammatory signaling in macrophages [68]. Kuhn et al.
conﬁrmedthatthedownregulationofmiR-25allowedforthe
upregulation of KLF4 [67].
TheroleofmiRNAsinasthmaisstillunderinvestigation;
however by identifying the role of certain miRNAs by up/
downregulation of its expression and measuring its eﬀects
on overall gene expression (microarray) or using prediction
software to predict genes which the miRNA may bind to
and following this up by Real time PCR, researchers are
slowly identifying the function of particular miRNA. In the
future, miRNA may provide a source of novel treatments and
therapies.
11. Challenges for Gene-Expression
Microarray Projects
Despite numerous advantages, the use of microarrays still
has many limitations, mainly relating to the experimental
design, sample variance, and the statistics used to analyze the
accumulated data. The challenges of microarray statistics in
complex diseases have previously been extensively reviewed
[69] and will not be discussed here.
11.1. Experimental Design. One of the main limitations of
microarray studies today is still the cost; however this is
slowly decreasing. In the past, cost was a major burden, often
limitingthenumberofpatients/samplesanalyzedinprevious
microarray studies; Jarai et al. and Yuyama et al. looked at
the eﬀect of Th-2 cytokines on human bronchial epithelial
cells (n = 3) and primary ASM cells (n = 2) [23, 34].
Another contributing factor to the lack of patients analyzed
is the concept of replicates versus treatments; when dealing
with a limited number of arrays a decision one must make
is whether to sacriﬁce the number of replicates to allow for
an increase in the number of treatments studied, or vice
versa. Traditionally, when dealing with diﬀerent treatments
of the same cell type which encompass the majority of
asthma-related microarray studies, studies were designed to
increase the number of treatments. The low patient/sample
per treatments number was then overcome by conducting
followup experiments such as Quantitative Real-time PCR
and/or ELISA with a greater patient pool on single candidate
genes [23, 34]. However, this still leaves an extensive list of
genes to followup which is usually impractical with these
alternative methods.
11.2. Sample Variance. Factors such as patient-to-patient
variation and the heterogeneity of the asthma phenotype
can make microarray data unreliable and hard to replicate.
Therefore, it is important that the right type and number
of patients are selected for each study, hence reducing
the variation within the samples. A problem that many
asthma studies face is obtaining samples with similar asthma
diagnoses. Using patients who have the same level of severity
of asthma and diagnosis using the same deﬁned method
can help reduce this variation. Also, it is important to
ensure that the patients analyzed have no other underlying
airway disease or other comorbidity. Accessing samples from
pure patient populations can be challenging; however it can
greatly decrease the number of false positives within the
resulting microarray dataset.
12.Accessing PreviousMicroarrayStudy Data
In 2002, the Nature family of journals adopted the mini-
muminformationaboutmicroarrayexperiments(MIAMEs)
standard (developed by the Microarray Gene Expression12 Journal of Allergy
Data Society (MGED) [70]), making it mandatory that all
microarray data (including annotations) used in publish-
able research must be deposited into an acceptable public
repository (NCBI Gene Expression Omnibus (GEO) [71],
ArrayExpress [72], or Center Information Biology Gene
Expression Database (CIBEX) [73], prior to the submission
of a manuscript [74]. There are six key elements within the
MIAME guidelines which authors must provide:
(1) raw data for each microarray (e.g., cel ﬁles),
(2) the processed normalized data,
(3) annotation of the samples used to conduct the mi-
croarrays (treatment, cell types, etc.),
(4) the experimental design,
(5) annotation of the array itself (coordinates of probes
and their sequences),
(6) methods of normalizing the data to obtain the
processed data.
Over the years, many other journals have also adopted
the MIAME standard, turning GEO (http://www.ncbi.nlm.
nih.gov/geo/) into a free microarray database containing
∼20,000 microarray studies to date [75]. Because this
information is freely available, researchers now have the
opportunity to design speciﬁc questions and search for a
previous microarray project to help narrow down the list
of candidate genes involved with their function of interest;
the GEO accession numbers for all microarrays’ studies
discussed in this review are highlighted in Table 4.H o w e v e r ,
not all the scientiﬁc community believe that the MIAME
guidelines are beneﬁcial. A number of critics have expressed
the view that forcing groups to disclose their microarray
data upon publishing has led to many to groups simply not
publishingtheirﬁndings.Whetherthisrestrictionisresulting
in a biased reporting of the application of microarrays in
researchisyettobedetermined.Anotherissueistheinability
of researchers to repeat the analysis of published expression
microarrays in MIAME abiding journals. This problem was
recently discussed in a paper by Ioannidis et al. [76]. In
this study Ioannidis and colleagues attempted to replicate
the data analyses in 18 articles on microarray-based gene
expression published in Nature Genetics in 2005-2006. Of
the 18 articles ten could not be reproduced [76]. The main
reasons for this were data unavailability (even though these
articles were published under the MIAME guidelines) and
incomplete data annotation not abiding by the MIAME
guidelines [76]. Based on this study and a number of reviews
it is clearly evident that MIAME provides a method of
allowingresearcherstoshareandscrutinisemicroarraybased
data by providing the necessary information; however it is
onlyaseﬀectiveastheenforcementthatjournalswhichabide
by these guidelines impose on researchers to make sure that
they follow them correctly [76, 77].
13. Conclusion
Microarrays have signiﬁcantly increased our understanding
of the genes and cell types involved with asthma. Although
the use of microarrays in asthma research is still at an
early stage, it has helped conﬁrm the results of previous
studies and has identiﬁed a number of novel genes which
warrant further, investigation. As the price of microarrays
decreases and the technology advances further the use of
microarrays in asthma-related research will expand and may
provide exciting new insights into the genetic regulation of
this complex pathological process.
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